Living with MS means adjusting to new challenges, and for columnist Desiree Lama, one of those things is an itch she can't ...

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...

Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the ...

The FDA has expanded approval of dupilumab to include children aged 2 to 11 years with chronic spontaneous urticaria who ...

The FDA approved dupilumab for children aged 2 to 11 years with uncontrolled CSU—the first biologic for this pediatric population. The approval extends the indication previously approved in April 2025 ...

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly ...

Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin ...

The expanded approval was based on data extrapolated from Study A, B, and C of the LIBERTY-CUPID program and supportive pharmacokinetics data from the single-arm CUPIDKids study.

Alabama Lt. Gov. Will Ainsworth advised other outdoorsmen to proceed with caution after he recently tested positive for Rocky ...